Prelude Capital Management’s Provention Bio, Inc. Common Stock PRVB Stock Holding History

Prelude Capital Management’s Portfolio PRVB Stock Details PRVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-202,015	Closed	-$4.87M	–	1495
2023 Q1	$4.87M	Buy	+202,015	New	+$2.54M	0.29%	64
2022 Q3	–	Sell	-12,064	Closed	-$48K	–	2101
2022 Q2	$48K	Buy	+12,064	New	+$57.2K	﹤0.01%	1486
2021 Q3	–	Sell	-11,300	Closed	-$95K	–	2131
2021 Q2	$95K	Buy	+11,300	New	+$91.2K	﹤0.01%	1485

Other funds holding PRVB

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Prelude Capital Management's PRVB Position: Q2 2023 in Review

Prelude Capital Management sold out of Provention Bio, Inc. Common Stock (PRVB) in Q2 2023, closing a stake of 202,015 shares — an estimated $4.87M sold.

Prelude Capital Management first reported a position in PRVB in Q2 2021 and held it in 3 quarters. The position peaked at $4.87M in Q1 2023. 1 fund tracked by Wall St. Rank holds PRVB as of Q2 2023.

Prelude Capital Management reported no remaining Provention Bio, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Prelude Capital Management sold 202,015 Provention Bio, Inc. Common Stock shares in Q2 2023, an estimated $4.87M.
Prelude Capital Management first reported a position in Provention Bio, Inc. Common Stock in Q2 2021 and held it in 3 quarters.
Prelude Capital Management's Provention Bio, Inc. Common Stock position peaked at $4.87M in Q1 2023.
1 fund tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q2 2023.

Based on Prelude Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.